Sessions

REVOLUTIONISING VIRAL VECTOR DEVELOPMENT IN EUROPE
EUROPEAN EXPANSION; MANUFACTURING HIGH QUALITY, LOW COST & LARGE VOLUME CELL & GENE THERAPIES
DEVELOPING A COMMERCIALLY ROBUST SUPPLY CHAIN ACROSS THE EUROPEAN CONTINENT
EXPLORING THE SHIFT TOWARDS POINT OF CARE AUTOMATION & DECENTRALISED MANUFACTURING
EUROPEAN SCALABILITY CONSIDERATIONS TO INDUSTRIALISE EARLY ACADEMIC TRANSLATION

REVOLUTIONISING VIRAL VECTOR DEVELOPMENT IN EUROPE

01 Sep 2022
13:30
SPONSORED BY
Pall Corporation

13:30 – CHAIR INTRODUCTION

Chair: TBC

 

13:35 – FIRESIDE CHAT

Speakers:

Takis Athanasopoulos, Head of Vector Innovation & Vector Development Cell & Gene Therapy, GSK

Hemant Dhame, Head of Process Development – Gene Therapy Vector Facility, King’s College London

 

14:00 – CASE STUDY: SCALABLE PURIFICATION OF RECOMBINANT ADENO-ASSOCIATED VIRAL VECTORS 

Speakers: Emmanuelle Cameau, Strategic Technology Partnership Leader – Cell & Gene Therapy, Pall Corporation

 

14:20 – CASE STUDY:

Speaker: Hemant Dhame, Head of Process Development, King’s College London

 

14:40 – Q&A WITH SESSION SPEAKERS

Speakers:

Emmanuelle Cameau, Strategic Technology Partnership Leader – Cell & Gene Therapy, Pall Corporation

Hemant Dhame, Head of Process Development, King’s College London

Speakers

Takis Athanasopoulos
Director, Head of Patient Operations, Product Development & Supply Cell & Gene Therapy
GSK
Emmanuelle Cameau
Strategic Technology Partnership Leader
Pall Corporation
Hemant Dhamne
Head of Process Development - Gene Therapy Vector Facility
King’s College London